Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’), especially in the field of supply reduction initiatives, and must be estimated using modelling approaches.
Drug-related public expenditure has been estimated for more than a decade, and the methodology used is currently being revised and improved. In 2017, total drug-related expenditure amounted to 0.08 % of Cyprus’s gross domestic product (GDP). The total expenditure of approximately EUR 15 million was divided into three main areas: law enforcement, healthcare and education.